This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

Brexit Announcements

PCI Brexit Communication, August 2019

Since the announcement in June 2016 that the UK will leave the EU, we have been regularly communicating to reassure you that PCI Pharma Services has a robust ‘Brexit plan’ to ensure the continuity of EU supply chains. This plan included the acquisition of an EU facility (Millmount Healthcare), located near Dublin, Ireland with the first phase of construction being a Clinical Storage and Distribution facility and a full analytical release testing laboratory allowing method transfer for release of commercial products. We are delighted that both the Clinical Storage and Distribution facility and the laboratory are both HPRA licenced and fully operational.

Irrespective of the final outcome of Brexit, PCI Pharma Services has always committed to ensuring that the security of your supply chain and management of your products will be maintained via our UK sites and our EU facilities and we will be working closely with you to ensure this process is managed effectively.

We will shortly be announcing our exciting plans for the second phase of expansion of PCI’s European facilities which will include significantly increased capacities and packaging capabilities which forms part of our overall global site expansion strategy.

As you have read from the above, the UK Government Brexit position is very fluid with the Brexit negotiations continuing. Over the coming months we will endeavour to keep you updated with announcements, including our EU expansion plans and any implications they may have to client supply chains. In the meantime, if you do have any questions, please contact your Project Manager, Commercial Account Manager, Business Development Manager or the PCI Brexit team brexit@pciservices.com

Salim Haffar, CEO & President

Please feel free to contact the PCI Brexit team brexit@pciservices.com


Please feel free to download and view our Brexit updates and factsheets


Update: August 2019

Since the announcement in June 2016 that the UK will leave the EU, we have been regularly communicating to reassure you that PCI Pharma Services has a robust ‘Brexit plan’ to ensure the continuity of EU supply chains. This plan included the acquisition of an EU facility (Millmount Healthcare), located near Dublin, Ireland with the first phase of construction being a Clinical Storage and Distribution facility and a full analytical release testing laboratory allowing method transfer for release of commercial products.

Download here

Update: 6th August 2019

We have been regularly communicating to assure you that PCI Pharma Services has a robust ‘Brexit plan’ to ensure the continuity of EU supply chains. This plan has included the acquisition of an EU facility (Millmount Healthcare), located near Dublin, Ireland, and has evolved with the completion of the first phase of construction of a Clinical Storage and Distribution facility and a full analytical release testing laboratory allowing method transfer for release of commercial products.

Download here

Update: July 2019

On 11th April 2019, the European Council and the UK Prime Minister, Theresa May announced an extension to Article 50 with a flexible Brexit delay until 31st October 2019. The intent during this period is for the UK Parliament to re-negotiate the Withdrawal Agreement and should agreement be reached, the UK will enter into transition arrangements.
Download here

Update: 12th April 2019

We are writing to you today to advise that the European Council and the UK Prime Minister have agreed and announced an extension to Article 50 with a flexible Brexit delay until 31st October 2019, with a review at the end of June. However, the UK will be able to leave the EU before this October date should a deal be agreed by UK Parliament.
Download here

Update: 3rd April 2019

On the 29th March 2019, a vote took place on the proposed first stage of the renegotiated Brexit deal by the United Kingdom (UK) Parliament. The plan was subsequently rejected and as a result, the extended deadline agreed during the EU Summit on the 21st March 2019 for the UK to leave the European Union (EU) remains as the 12th April 2019.
Download here

Update: 15th March 2019

On 13th March, the United Kingdom (UK) Parliament voted in favour of leaving the European Union (EU) with a Brexit deal. A further vote took place on 14th March in favour of extending Article 50 (the UK/EU Withdrawal Agreement) beyond 29th March, however this will now require agreement from EU leaders at an EU Summit on 21st March.
Download here

Update: 22nd January 2019

The UK Government Cabinet and European Leaders have formally agreed the plan for the departure of the UK from the European Union. However until the plan is agreed by members of the UK Parliament (scheduled around 12th December), there still remains uncertainty over the future of the relationship between the UK and Europe post 29th March 2019
Download here

Update: CPhI October 2018

PCI Services is currently planning for a hard Brexit meaning that should the UK government trade negotiations not result in any agreement and the UK is entirely outside the European framework following the 29th March 2019 date, it is anticipated that materials QP released within the UK will not be recognized by the European Union
Download here

Factsheet: Clinical Services

View the PCI Clinical Services Brexit Regulatory Risk Mitigation for EU Clinical Trial Applications
Download here

Factsheet: Commercial Activities

View the PCI Pharma Services Brexit Regulatory Risk Mitigation for EU Commercial Activities
Download here



PCI Pharma Services Completes Expansion of its Specialty Drug Product Capabilities at Rockford, IL Site

Increases Capacity at State-of-the-Art Facility in Response to Growing Market Needs PHILADELPHIA–(BUSINESS WIRE)–PCI Pharma Services (PCI), a leading pharmaceutical and... View Article

PCI Unveils Clinical Center of Excellence

Expanded Clinical Services Facility in Rockford, IL to Support Growth and Flexibility with 30,000 additional sq ft We have officially... View Article

x